Cannabis compound can slow tumour growth

The main psychoactive ingredient in cannabis could reduce tumour growth in cancer patients, scientists say.
Researchers at the University of East Anglia in UK and colleagues have discovered previously unknown signalling platforms which are responsible for the drug's success in shrinking tumours.
It is hoped that the research co-led with the Universidad Complutense de Madrid, Spain could help develop a synthetic equivalent with anti-cancer properties.
The team used samples of human cancer cells to induce tumours in mice. They then targeted the tumours with doses of the cannabis compound THC (Tetrahydrocannabinol).
They found that two cell receptors in particular were responsible for the drug's anti-tumour effects.

"THC, the major active component of marijuana, has anti-cancer properties. This compound is known to act through a specific family of cell receptors called cannabinoid receptors," said Dr Peter McCormick, from UEA's school of Pharmacy.

"However, it was unclear which of these receptors were responsible for the anti-tumour effects of THC.
"We show that these effects are mediated via the joint interaction of CB2 and GPR55 - two members of the cannabinoid receptor family.
"Our findings help explain some of the well-known but still poorly understood effects of THC at low and high doses on tumour growth," he said.
McCormick added that cancer sufferers should not be tempted to self-medicate.

"Our research uses an isolated chemical compound and using the correct concentration is vital. Cancer patients should not use cannabis to self-medicate, but I hope that our research will lead to a safe synthetic equivalent being available in the future," McCormick said.
The research is published in the Journal of Biological Chemistry.